PPBT VS AKU Stock Comparison

Performance

PPBT
10/100

PPBT returned -52.51% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

AKU
10/100

AKU returned -83.78% in the last 12 months. Based on SPY's performance of -19.63%, its performance is below average giving it a score of 10 of 100.

Technicals

PPBT
11/100

PPBT receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

AKU
79/100

AKU receives a 78 of 100 based on 14 indicators. 10 are bullish, 2 are bearish.

Earnings

PPBT
10/100

PPBT has missed earnings 7 times in the last 20 quarters.

AKU
10/100

AKU has missed earnings 5 times in the last 20 quarters.

Profit

PPBT
11/100

Out of the last 20 quarters, PPBT has had 1 profitable quarters and has increased their profits year over year on 0 of them.

AKU
26/100

Out of the last 20 quarters, AKU has had 8 profitable quarters and has increased their profits year over year on 2 of them.

Volatility

PPBT
48/100

PPBT has had a lower than average amount of volatility over the last 12 months giving it a score of 48 of 100.

AKU
36/100

AKU has had a lower than average amount of volatility over the last 12 months giving it a score of 36 of 100.

Sentiment

PPBT

"Sentiment" not found for PPBT

AKU
74/100

AKU had a bullish sentiment score of 73.78% across Twitter and StockTwits over the last 12 months. It had an average of 30.80 posts, 8.50 comments, and 40.60 likes per day.

All score calculations are broken down here to help you make more informed investing decisions

Purple Biotech Ltd. American Depositary Shares Summary

Nasdaq / PPBT

Healthcare

Biotechnology

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer; and NT219, a small molecule that targets insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.

Akumin Inc. Common Stock (DE) Summary

Nasdaq / AKU

Healthcare

Diagnostics & Research

Akumin Inc. provides outpatient diagnostic imaging services in the United States. It operates in two segments, Radiology and Oncology. The company offers various medical imaging services, including magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, digital radiography, fluoroscopy, and other diagnostic or interventional radiology procedures through a network of approximately 200 owned and/or operated imaging locations. It provides outpatient radiology, and oncology services and solutions to approximately 1,000 hospitals and health systems across 46 states. Akumin Inc. was founded in 2015 and is headquartered in Plantation, Florida.

Power up your portfolio